Relatox was created at Microgen Laboratories of Nacimbio Holdings and appeared in the market in 2014. An analog to the foreign produced Botox, Relatox has become a successful example of import substitution with nationally produced products in cosmetology and pharmacy. Now Microgen is working on both product improvement and production development setting up modern manufacturing facilities. A new production line is expected to be put into operation this year.
Tons of botulinum toxin worth millions of dollars are reportedly being imported into Russia yearly. About 80 per cent of that amount is used in cosmetology with the rest designated for medical purposes to treat hemiparesis, including infantile cerebral paralysis; postapoplectic conditions and other diseases.
An analog to the foreign produced Botox, Relatox has become a successful example of import substitution with nationally produced products in cosmetology and pharmacy. Microgen Laborotories started their research to develop the product in 2001.
Upon completion of a medical research study in March 2012 Relatox was awarded a five-year registration certificate. During the five-year period of use over 30,000 patients received the injections of the medication. Relatox has proved its efficiency and has won recognition with both medical personnel and patients. In March 2017 the medication was approved for its registration renewal and was enlisted in the state register of medications on a permanent basis.
As a cosmetology product in Russia Relatox is used alongside with its five imported analogs. According to market professionals, Relatox is not worse than any other product, including Botox; in some ways is even better than others. The product’s cosmetic effect lasts for 4 to 6 months while the unique purifying technology makes it possible to get rid of up to 90 per cent of high-molecular protein impurities to decrease protein burden and minimize allergic reaction.
Microgen botulinum toxin is used outside cosmetology as well. Since September 2016 Relatox has authorized for use as a medication to cure some neurological diseases, e.g. postapocleptic complications. Currently, Microgen is working on both product improvement and production development setting up modern manufacturing facilities. A new production line at Microgen subsidiary in Ufa has already been certified and is expected to be put into operation by the end of the year. Its output capacity is estimated at 200,000 packages per year.
